Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

@article{Jacobs2000IntramuscularIB,
  title={Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.},
  author={Lawrence D. Jacobs and Roy W. Beck and Jack Simon and R. P. Kinkel and Carol M. Brownscheidle and T. John Murray and Nancy A. Simonian and Peter Slasor and Alfred W. Sandrock},
  journal={The New England journal of medicine},
  year={2000},
  volume={343 13},
  pages={
          898-904
        }
}
BACKGROUND Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical demyelinating event is of value. METHODS We conducted a randomized, double-blind trial of 383 patients who had a first acute clinical demyelinating event (optic neuritis, incomplete transverse myelitis, or brain-stem or cerebellar syndrome) and evidence of prior subclinical demyelination on magnetic… 
View on PubMed
direct-ms.org
1,482 Citations
Highly Influential Citations
40
Background Citations
211
Methods Citations
35
Results Citations
42

1,482 Citations

Citation Type

Citation Type

Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
TLDR
Intravenous immunoglobulin treatment for the first year from onset of the first neurological event suggestive of demyelinative disease significantly lowers the incidence of a second attack and reduces disease activity as measured by brain magnetic resonance imaging.
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event
TLDR
The results of a 5-year, open-label extension of CHAMPS indicate that there may be modest beneficial effects of immediate treatment compared with delayed initiation of treatment and support the use of IM interferon beta-1a after a first clinical demyelinating event.
Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses
TLDR
Interferon β‐1a is beneficial when initiated at the first clinical demyelinating event in patients with brain magnetic resonance imaging evidence of subclinical demYelination and the beneficial effect is present for optic neuritis, brainstem–cerebellar syndromes, and spinal cord syndrome.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
TLDR
Interferon beta-1b treatment had a robust effect on MRI measures, supporting its value as an early intervention in this patient group, and this effect was maintained despite including patients who switched from placebo to interferonBeta1b in the active treatment group.
Intramuscular Interferon-β-1a
TLDR
Intramuscular interferon-β-1a was generally well tolerated; however, influenza-like syndrome was documented in >50% of patients at high risk of developing clinically definite MS who received the drug.
Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
  • G. Comi
  • Medicine, Psychology
    Clinical therapeutics
  • 2009
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
TLDR
Interferon beta-1b 250 μg subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
TLDR
Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
  • G. Ebers
  • Medicine, Psychology
    The Lancet
  • 1998
Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis
TLDR
Once weekly intramuscular IFNβ‐1a appears to impede the development of multiple sclerosis lesions at an early stage and has a favorable impact on the long‐term sequelae of these inflammatory events as indicated by the slowed accumulation of T2 lesions.
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
TLDR
The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
TLDR
NAB directed against IFN-β have in vivo biological consequences in patients with MS and treatment decisions in MS patients treated withIFN- β should take into account development of NAB.
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.
TLDR
Brain MRI at presentation with a clinically isolated syndrome is predictive of the long-term risk of subsequent development of multiple sclerosis, the type of disease and extent of disability.
The 5-year risk of MS after optic neuritis
TLDR
Lack of pain, the presence of optic disk swelling, and mild visual acuity loss were features of the optic neuritis associated with a low risk of CDMS among the 189 patients who had no brain MRI lesions and no history of neurologic symptoms or optic neuropathy in the fellow eye.
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.
TLDR
Quantification of changes detected by T2-weighted brain MRI at the earliest clinical stages is strongly predictive of the subsequent development of CDMS as well as the clinical course and level of disability 10 years later.
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
TLDR
The brain parenchymal fraction is a marker for destructive pathologic processes ongoing in relapsing MS patients, and appears useful in demonstrating treatment effects in controlled clinical trials.
Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis
TLDR
It was found that abnormal IgG levels in the cerebrospinal fluid correlated more strongly than abnormal MRIs with the subsequent development of clinically definite MS.
...
1
2
3
...